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We report the results of a phase II trial in patients with metastatic endocrine tumours from different sites, which aimed to evaluate
the anti-tumour activity and toxicity of a cisplatinum and etoposide regimen administered in combination with the somatostatin
agonist lanreotide given in slow release formulation. Between January 1999 and November 2003, 27 patients with histological
diagnoses of endocrine tumours with different degrees of differentiation, excluding well differentiated carcinoid neoplasms, received
intravenous (i.v.) administration of cisplatinum (30mgm
 2) and etoposide (100mgm
 2) on days 1–3 and intramuscular
administration of 60mg lanreotide on day 1, in a 21-day cycle. All of the patients were evaluable for toxicity and response. The
treatment was very well tolerated as no grade 4 toxicity was observed. Four patients achieved a complete response, six a partial
response, 12 experienced disease stabilisation and five disease progression. The average time to progression and to survival were 9
and 24 months respectively. These results suggest that this chemo-hormone therapy regimen is well tolerated and active in patients
with non-well differentiated endocrine tumours.
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Non-differentiated endocrine tumours represent a heterogeneous
and controversial group of neoplastic diseases, whose existence has
been largely underestimated, as they are often reported as mixed,
undifferentiated, or anaplastic malignancies (Buchanan et al, 1986;
Moertel, 1987; Greco and Hainsworth, 2005; Jensen and Doherty,
2005). These tumours may arise from any organ or tissue
undertaking neuroendocrine control, such as respiratory, gastro-
enteric, and urinary tracts, as well as secretory glands like the
prostate, breast, and pancreas, and usually present common
phenotypic and functional features (Buchanan et al, 1986; Moertel,
1987; Greco and Hainsworth, 2005; Jensen and Doherty, 2005).
Neuroendocrine cells derive from the same multi-potent stem
cells that are responsible for either cutaneous or mucosal tissue
replacement. On the basis of their original genotypic programme,
and in response to specific environmental stimuli, these multi-
potent cells may differentiate in somatic epithelial cells (glandular,
cutaneous, or mucosal cells) or cells with neurosecretive potential
and neurovegetative control capability (Buchanan et al, 1986;
Moertel, 1987; Langley, 1994; True, 2004; Gordon et al, 2005; Long
et al, 2005; Sauer et al, 2006).
Similarly, tumour cells with neuroendocrine phenotype derive
from stem cells genetically altered to progress into cancer (through
inherited and/or acquired mutations). In this case, the derivative
cells may dynamically undergo a caricatural differentiation that
may resemble epithelial, glandular, or neuroendocrine cells. On the
basis of different kinds and levels of molecular and genetic
alterations, these cells may follow distinct differentiation pathways
and may stop their distinct differentiation programmes at different
stages of maturation (Buchanan et al, 1986; Hansson and
Abrahamsson, 2003; Wright et al, 2003; Bishop, 2005; Long et al,
2005). Respiratory, gastroenteric, and urinary tracts, as well as the
prostate, are physiologically under strict neurovegetative control,
and so it is not surprising that the majority of neuroendocrine
tumours arise in these anatomic sites. Neuroendocrine tumours
may manifest at different degrees of differentiation, from well-
differentiated (carcinoids) to poorly differentiated, or anaplastic or
somatic/neuroendocrine mixed forms. In some cases, they may be
very difficult to recognise because there is no single marker to
identify an undifferentiated neuroendocrine tumour; so, diagnosis
must rely on the correct interpretation of pathological data
(histology, immunohistochemistry, and sometimes electronic
microscopy), biohumoral studies, blood/urinary tests, biological
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sbehaviour of the neoplasia, the natural history and the progression
of the disease, and patients’ symptoms (Wiedenmann and Huttner,
1989; Polak, 1993; Nicholson and Ryan, 2000; De Lellis, 2001;
Bishop, 2005). Neuroendocrine tumours may arise with clinically
different modalities and signs (paraneoplastic syndromes), which
are often related to the different degrees of biological aggressive-
ness and to the different levels of production of specific hormones
and peptides (Buchanan et al, 1986; Moertel, 1987). When well
differentiated, they retain a low level of local and metastatic
aggressiveness. However, they often give rise to endocrine
syndromes related to the inappropriate production of peptides
and amines with different hormonal profiles. These include
neuron-specific enolase (NSE), 5-hydroxytryptamine (5-HT), 5-
hydroxytryptophan (5-HTP), synaptophysin, chromogranins A
and C, other peptides such as insulin, growth hormone,
neurotensin, adrenocorticotropic hormone (ACTH), b-melano-
cyte-stimulating hormone, gastrin, pancreatic polypeptide, calci-
tonin, substance P, various other tachykinins (neuropeptide K),
growth hormone–releasing hormone (GHRH), bombesin, and
various growth factors such as transforming growth factor (TGF)-
b, platelet-derived growth factor (PDGF), and fibroblast growth
factor (FGF)-b (Fenoglio-Preiser, 2001; Oberg, 2002), many of
which exert a powerful functional activity.
The less differentiated, anaplastic, and mixed forms are
considered to be much more aggressive than the well-differentiated
forms and are believed to be much more aggressive than their
epithelial and glandular counterparts. Similar to small cell lung
cancer, which belongs to this family of neoplasms, they are much
more responsive to specific anti-cancer treatments and are very
sensitive to platinum-based polychemotherapy (Mitry et al, 1999;
Mitry and Rougier, 2001; Singhal et al, 2006).
The possibility of a phenotypic switch of advanced tumours
from adenocarcinoma (mainly of the prostate and pancreas) to a
neuroendocrine phenotype has also been shown, and this fact
correlates with enhanced sensitivity to several cytotoxic drugs
(Mitry et al, 1999; Mitry and Rougier, 2001; Hainsworth et al, 2006;
Singhal et al, 2006). In this context, we have shown in a previous
study that drug-resistant colon cancer cells, driven to neuroendo-
crine differentiation following exposure to phorbol myristate
acetate in vitro, lose both the epithelial phenotype and their (type
I) multidrug-resistant phenotype, becoming highly sensitive to
topoisomerase II inhibitors such as adriamycin and etoposide
(Correale et al, 1994). The recognition of undifferentiated or
somatic/neuroendocrine mixed forms of endocrine tumours could
therefore have very important prognostic and therapeutic implica-
tions.
Sensitivity to somatostatin analogues (SSAs) is another chara-
cteristic aspect of these neoplasms. Tumour cells with neuro-
endocrine differentiation vary in their expression of functional
somatostatin receptors (SSTR), whose engagement and stimulation
with SSAs may produce efficacious cytostatic effects. Somatostatin
(SST) binding to SSTRs is known to be capable of interfering with
the production and release of many different classes of hormones
and growth factors (such as GH, IGF, VEGF) and to be able to
transmit a direct anti-proliferative message. Sensitivity to soma-
tostatin analoguess, alone or in combination with interferon a have
been used to treat well-differentiated and moderately well-
differentiated endocrine tumours and to control the carcinoid
syndrome (related to the inappropriate production of molecules
with hormonal activity) that is often associated with these tumours
(Kvols et al, 1986; Lamberts, 1999).
Considering this background, we hypothesised that the thera-
peutic use of SSAs such as lanreotide and octreotide, associated
with an efficacious polychemotherapy regimen, may represent an
active treatment for aggressive endocrine tumours and mixed
forms.
We therefore designed a phase II trial involving patients with
metastatic non-well-differentiated endocrine tumours deriving
from different anatomic sites, which aimed to evaluate the
antitumour activity and toxicity of a novel chemohormonal-
therapy regimen that combines a cytotoxic polychemotherapy with
(i.v.) cisplatinum (CDDP) and etoposide with the long lasting
release formulation of lanreotide SSA.
PATIENTS AND METHODS
The study protocol was approved by our local Ethics Committee,
and was performed in accordance with the good clinical practice
(GCP) guidelines. All patients gave their written informed consent.
The study involved 27 patients with histological diagnosis of non-
well differentiated and mixed endocrine tumours arising in
different anatomic sites (Table 1). All of the patients were at an
advanced stage of disease and all had an ECOG performance status
of p2 and a life expectancy of X3 months. To be enrolled in the
study, the patients had to have normal renal and hepatic function,
a white blood cell (WBC) count of 42500mm
 3, haemoglobin
levels of 49mgmm
 3, a platelet cell count of 490000mm
 3, and
a cardiac ejection fraction of 446%. The exclusion criteria were:
well-differentiated carcinoid tumours; poor performance status
(ECOGX3); severe valvular and wall motion abnormalities or
cardiac failure; arrhythmia, central nervous system (CNS)
metastases; secondary malignant tumours; signs of active hepatitis
or liver failure; chronic or acute renal failure; active infectious
disease; or a history of other severe cardiovascular disease.
Study design
The phase II study was prospectively planned according to Simon’s
two-stage minimax design to test the hypothesis that our new
chemo-hormone therapy schedule combining CDDP, etoposide,
and lanreotide is an active treatment for patients with non-well
differentiated neuroendocrine tumours and mixed forms.
The minimax two-stage procedure was designed to test a null
hypothesis of Pp0.150 vs an alternative of PX0.350, with an
Table 1 Demographics
Characteristics No. of patients
Patients evaluable for response 27
Patients evaluable for toxicity 27
Age (years)
Median 63.5
Range 47–78
Sex
Male 22
Female 5
Performance status (ECOG) 0–3
Primary tumour
Lung 7
Thyroid 2
Gut 8
Pancreas 2
Prostate 4
Unknown 4
Previous surgery 13
Previous systemic treatment 4
None 5
One or more line of previous therapy 2
Carcinoid syndrome 23
Disease extension
Stage IV 27
(A) Liver involvement 12
(B) No liver involvement 15
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sexpected sample size of 20.15 and a probability of early
termination of 0.604. In these conditions, if the combination is
not considered to be active, there is only a 0.046 probability (4.6%)
of discharging an active treatment (the target for this value was
0.050); conversely, if the regimen is found to be active, there is a
0.197 probability (19.7%) that it is actually not active (the target
for this value was 0.200). The objective response rate (CRþPR)
was the primary end point for the statistical analysis, while the
disease control rate and the time to progression were secondary
end points. For this study, we selected a 15% response rate as a
null hypothesis and a 35% response rate as an alternative
hypothesis, with a 0.05a-error and a 0.20b-error. In this case, the
treatment under investigation should be considered inactive if less
than 2 responses are recorded out of 15 consecutive patients in the
first series and fewer than 7 responses out of 28 patients in the
whole series (Hintze, 2004). We considered the regimen as active
when a response rate of 35% was recorded, considering that the
trial did not exclude patients receiving second-line treatment.
Furthermore, the study was designed to involve patients with non-
well-differentiated endocrine tumours, whose histological analysis
showed different levels of neuroendocrine differentiation, and was
not limited to the small cell and anaplastic forms that are highly
sensitive to platinum-based polychemotherapy regimens.
Patient treatment
Twenty-seven patients with non-well-differentiated endocrine
tumours were enrolled in the study and gave their written
informed consent, and received treatment with i.v. CDDP
(30mgm
 2 days 1–3), i.v. etoposide (100mgm
 2 days 1–3) and
i.m. lanreotide given as a long-lasting release formulation (60mg
day 1) in a 21-day cycle. Standard premedication with mannitol,
corticosteroids, anti-emetic, and gastroprotective drugs was given
to all patients before cytotoxic drug administration.
Baseline and on-treatment clinical assessments
Before treatment, a complete medical history was taken of all
patients who also underwent physical examination, a complete
blood count, serum chemistry tests, and complete disease staging
by means of chest X-rays, brain, chest, and abdominal computed
tomography (CT), and liver and pelvic ultrasound. Considering
that patients with endocrine tumours may be affected by
paraneoplastic cardiopulmonary alterations (paraneoplastic fibro-
sis), an ultrasound investigation and ventricular function and
pulmonary volume analysis were performed on all patients. The
staging examinations were repeated every 2 months, whereas full
blood counts, biochemistry profile, liver function tests, electro-
cardiography (ECG), chest X-rays, and urine analysis were
performed weekly.
Toxicity and response criteria
All eligible patients were evaluated for survival and toxicity, and
they were considered evaluable for response when they had
completed three treatment cycles. If the patients responded or had
stable disease, the treatment was continued until the occurrence of
disease progression or unacceptable toxicity. Overall survival was
measured from the date of diagnosis to the date of death or the
date of the last follow-up examination. Time to progression was
evaluated from the beginning of treatment to the demonstration of
disease progression or the date of the last follow-up examination.
Response and toxicity were assessed using standard WHO criteria.
A complete response was defined as the complete disappearance of
all known measurable disease for at least 1 month, while a partial
response was defined as a decrease of almost 50% in known lesions
lasting for at least 1 month. The area of two-dimensional lesions
was defined as the product of the longest diameter multiplied by
the greatest perpendicular diameter; disease stabilisation was
defined as a o50% decrease or o25% increase in evaluable lesions
lasting for 1 month without the appearance of new lesions, and
progressive disease was defined as a 425% increase in known
disease or the appearance of new lesions (WHO criteria).
RESULTS
Demographics
Twenty-seven patients with a histological diagnosis of metastatic
non-well-differentiated endocrine tumours were enrolled in the
study and received treatment between January 1999 and November
2003. There were 22 men and five women, with an average of 63.5
years of age. Twenty-three of them presented at least one sign of a
typical or atypical carcinoid syndrome at diagnosis. Twelve of
them showed liver metastases, whereas 13 had previously under-
gone surgery and six had previously received a 5-fluorouracil
based line of chemotherapy. Other characteristics are shown in
Table 1. No patients with a pathological diagnosis of anaplastic
malignancy, well-differentiated endocrine tumour or localised
carcinoid tumour were enrolled in the study.
Toxicity
A median of 20 weeks of treatment was administered per patient
(range 15–24). The treatment was very well tolerated as no grade 4
toxicity was observed. No patients died during the treatment.
Grade III haematological toxicity was the most common adverse
event. Febrile neutropenia and anaemia were both reversible with
the administration of specific growth factors. Thrombocytopenia,
on the other hand, delayed treatment by 1 week in 25% of the
cases. All patients were able to receive full doses of CDDP and
etoposide for the entire treatment programme. No cases of grade
III-IV diarrhoea, mucositis, oliguria, hypotension, or transaminase
elevation were observed during the treatment (Table 2).
Response
This study was designed with the intention to treat thus, all the
patients were taken in consideration (Table 3). We observed a 37%
objective response rate (four complete and six partial) and 81.5%
disease control rate (10 objective responsesþ12 disease stabilisa-
tions). Only five patients experienced rapid tumour progression.
The signs of carcinoid syndrome were completely reversed in all
patients within the first week of treatment, which appeared to be
associated with significant reduction of the urinary levels of HT,
Table 2 Toxicity
Grade III and IV toxicity episodes (27 patients) No. of events
Total courses 135
Thrombocytopenia 15
Anaemia 14
Neutropenia 25
Infection 4
Fever 16
Malaise 3
Pulmonary distress 1
Nausea/vomiting 1
Diarrhoea 0
Oliguria (o80cc/8h) 0
Creatinine (48mg/dl) 0
Arrhythmia 0
Hypotension 0
CNS-level of conscience 0
CNS-orientation 0
Hyperbilirubinemia 0
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shown). All responsive patients (ORþs.d.) showed a significant
reduction in seric chromogranin A, with blood levels dropping
from 65 (727) to 15 (712) Ul
 1 (Po0.05).
In this study, we recorded a very long median time to
progression and relative survival of 9 months (95% CI¼3–36),
and 24 months (95% CI¼10–36) respectively. The average follow-
up of these patients was 44 months. Six patients, who achieved an
objective response or showed disease stabilisation, were alive 48
months from enrolment. Among these six patients, the primary
tumour site was unknown (two cases), or derived from the
pancreas, lung, prostate or thyroid (one case each). With the
exception of the last patient, who was diagnosed with a medullary
thyroid carcinoma on secondary pathological revision, all of the
others had a histological diagnosis of undifferentiated endocrine
tumour.
DISCUSSION
The results of our study suggest that a regimen based on the
combined use of standard polychemotherapy and hormonal
manipulation is a safe and active treatment for these patients.
The regimen was considered active in the treatment of these
malignancies, as a 37% objective response rate and a very high
disease control and symptom control rate were recorded. Many of
these patients had received a previous line of chemotherapy, and
some of them had histological features that were different from
small cell and other anaplastic forms, which are known to be very
sensitive to platinum-based polychemotherapy. We also recorded a
very long time to progression and survival — results that are
perfectly in line with the study’s rationale. The addition of an SAA
to this chemotherapy regimen is based on the knowledge that
SSTR 2, 3, 4, and 5 stimulation might have cytostatic effects on the
tumour cells that survived the cytotoxic drugs, thus preventing or
delaying their inter-cycle recovery. On this basis, we did not expect
the chemo-hormonal combination to significantly enhance the
tumour shrinking ability of the cytotoxic drugs, but we
hypothesised its ability to enhance the rate of disease stabilisation
in these patients, eventually prolonging their time to progression
and survival.
Several trials have investigated the effects of chemotherapy,
SAAs (either octreotide on lanreotide), and biological response
modifiers such as a-interferon in the treatment of these tumours,
achieving conflicting results in term of response rate, symptom
control, and survival (Kvols et al, 1986; Moertel et al, 1991; Di
Bartolomeo et al, 1995; Jensen, 1997; Bajetta et al, 1998, 2000, 2003,
2005; Rougier and Ducreux, 1999; Jensen and Doherty, 2001; Mitry
and Rougier, 2001; Oberg, 2002; Faiss et al, 2003; Hainsworth et al,
2006), mainly due to the very difficult classification of these
tumours and pathological analysis. Although equally able to
control hormonal symptoms by reducing the secretion of
biological amines and various peptides, these analogues exert a
poor tumoricidal effect, being able to decrease tumour size in less
than 15% of patients. However, SAAs possess a powerful
tumorostatic effect, being capable of stabilising the growth of
metastatic disease and prolonging survival (Jensen, 1997; Patel,
1997; Dierdorf, 2003; Faiss et al, 2003).
In this context, none has yet evaluated the possibility of
combining cytotoxic chemotherapy with the administration of
SSAs. We designed this regimen hypothesising that the adminis-
tration of SAAs between two subsequent administration cycles of
chemotherapy could sensitise tumour cells with neuroendocrine
differentiation to the apoptotic effect of many different cytotoxic
drugs, including CDDP and etoposide, and could contribute to
delaying the recovery of drug-resistant or less sensitive cancer cells
that usually occurs in the long (21–28 days) inter-cycle resting
period. We also speculated that the metronomic use of SSAs may
also synchronise the cell cycle of the tumour cells, thus making
them a much more sensitive target for the cycle-specific cytotoxic
drugs, enabling them to kill a greater fraction of in-cycle tumour
cells. Preclinical models also suggest an anti-angiogenetic effect of
SSAs that is believed to be able to reduce tumour production and
release of VEGF (Kumar et al, 2004) that could synergise with the
cytotoxic effects of chemotherapy. Finally, we considered that SSA
administration could improve tolerance to cytotoxic drugs by
possibly reducing the occurrence of gastroenteric toxicity (Low,
2004; Arabi et al, 2006). Currently only two SSAs are commercially
available for clinical use in Europe: octreotide and lanreotide.
Both were designed to bind the SSTR-2, whose stimulation of
neuroendocrine cells is believed to inhibit the secretion of
hormones and bioactive molecules, and they are currently
considered to be equivalent. The results of preclinical studies also
suggest that the SSA binding to SSTR-4 and -5 mediates a powerful
cytostatic activity, while SSTR-3 activates a pro-apoptotic pathway
(Li et al, 2005; Kvols and Woltering, 2006; Ruan et al, 2006). For
our study, we chose lanreotide over octreotide, considering that
there is no difference in SSTR-2-binding affinity and little
difference in SSTR-3 and SSTR-5 binding, while only lanreotide
is able to bind the cytostatic SSTR-4 (Patel, 1997). We believe that
more promising results will be obtained when more selective SST
analogues become available. In conclusion, we believe that the
results of this study provide the rationale to carry out a
randomised multicentre phase III trial to compare the efficacy of
our chemo-hormonal combination vs polychemotherapy with
CDDP and etoposide for the treatment of patients with non-well
differentiated endocrine tumours.
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